Piasky 340 mg/ 2 ml
As listed in the register: Piasky 340 mg/ 2 ml, Injektions-/Infusionslösung
340 mg/ 2 ml ·
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Crovalimabum
- Made by
- Roche Pharma (Schweiz) AG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- als Monotherapie für die Behandlung von erwachsenen und pädiatrischen Patienten ab 12 Jahren mit einem Gewicht von mindestens 40 kg mit paroxysmaler nächtlicher Hämoglobinurie (PNH): Bei Patienten mit Hämolyse mit klinischen Symptomen, die auf eine hohe Krankheitsaktivität hinweisen. Bei Patienten, die nach mindestens 6 Monaten Behandlung mit einem Komplement-5-Inhibitor klinisch stabil sind.
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Roche Pharma (Schweiz) AG |
|---|---|
| Active substance | Crovalimabum |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 340 mg/ 2 ml |
| Classification | L04AJ07 · Cancer treatments and immune-system medicines |
| Dispensing (as stated by the register) | Abgabekategorie A |
| Name in the register | Piasky 340 mg/ 2 ml, Injektions-/Infusionslösung |
| Packs | 1 Durchstechflasche(n) |
| Zulassungsnummer | 69340 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.